Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Pulmonary Embolism in anticoagulated patients: a retrospective single-centered cohort comparing data from the PIOPED II study
Session:
SESSÃO DE POSTERS 14 - CONGÉNITOS E HTP 2
Speaker:
Ana Rita Tomás
Congress:
CPC 2025
Topic:
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Theme:
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
Subtheme:
21.7 Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure - Other
Session Type:
Cartazes
FP Number:
---
Authors:
Ana Rita de Oliveira Tomás; Maria Carolina Silva; Rodrigo Brandão; Isabel Ribeiro Ferreira; Rúben Costa; Mónica Roxo Iglesias; Carolina Chumbo; Constança Coutinho; Daniela Madeira; Teresa Branco
Abstract
<p>Introduction: Pulmonary embolism (PE) is a prevalent and potentially fatal condition representing the third most frequent acute cardiovascular syndrome with an incidence reaching 115/100000 individuals annually. Although uncommon, cases of acute PE have been reported in patients undergoing anticoagulation (AC).</p> <p>Objectives: Review the characteristics of PE in patients receiving AC and compare these findings with data from individuals not under this treatment.</p> <p>Materials and methods: We conducted a retrospective single-center study including patients diagnosed with PE from January 2019 to December 2023 in medical wards of our hospital with 18 years or older. Patients whose PE did not represent a current diagnosis were excluded. Socio-demographic data, comorbidities, pharmacological treatments, and clinical outcomes were collected and analyzed using Excel®. The findings were compared with data from the Prospective Investigation of Pulmonary Embolism Diagnosis II (PIOPED II) study which included only patients not undergoing AC therapy. </p> <p>Results: Of the 1197 patients evaluated, 74 were excluded and 59 (7%) were anticoagulated at the time of PE diagnosis, mostly with direct oral anticoagulants (DOACs) (78%), specifically rivaroxaban (43%) or apixaban (33%), at appropriate doses, though 19% reported non-compliance. The mean age was 76±13 years vs. 57±17 in PIOPED II (p < 0,001). In the AC group, most PE were segmental (54%) but in PIOPED II there was a predominance of lobar PEs (77%) (p < 0,001). The most frequently reported signs and symptoms in both groups were dyspnea (56% in the AC group vs. 79% in PIOPED II), chest pain (27% vs. 64%), cough (37% vs. 43%), tachypnea (68% vs. 57%), tachycardia (81% vs. 26%), and respiratory failure (51% vs. 21%). SARS-CoV-2 infection (34%), previous venous embolism (25%), obesity (25%), immobilization (20%) and active cancer (19%) emerged as the most common risk factors (RF) in our cohort. Some patients had no identifiable RF (10% in our study and 6% in PIOPED II). Mortality in our study reached 29%, but equivalent data from PIOPED II was not available.</p> <p>Conclusion: PE in anticoagulated patients appears to occur in older individuals and in smaller pulmonary artery branches. This population does not exhibit a significantly different prevalence of symptoms or RF, and events may arise even in their absence. The low overall incidence of PE in anticoagulated patients and the predominance of segmental involvement suggests that current treatment strategies remain effective, potentially resulting in less severe outcomes. Due to lack of studies and consensus in literature, patient’s management is most often not evidence based. Further and larger studies are needed to identify high risk scenarios and to implement strategies such as DOAC level measurement to better predict recurrence, understand underlying mechanisms of treatment failure and guide appropriate approaches. </p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site